Letter to the Editor
Quinupristin–dalfopristin-induced Reticulocytopenic Anemia
Abstract
Quinupristin-dalfopristin was approved by the FDA in 1999 for bacteremia and life-threatening infections with vancomycin-resistantEnterococcus faecium. 1 Other indications include complicated skin and soft-tissue infections with methicillin-susceptible Staphylococcus aureus and Streptococcus pyogenes. 2 Quinupristin-dalfopristin has also been used for methicillin-resistant S aureus, coagulase-negative staphylococcus, and Streptococcus pneumoniae. 3 Adverse drug events (ADEs) associated with quinupristin-dalfopristin include infusion-site reactions (42%), infusion-site pain (40%), edema (17%), arthralgias (47%), myalgias (6%), gastrointestinal effects (3 to 5%), rash (2.5%), headache (1.6%), pruritus (1.5%), and hyperbilirubinemia (25%).1,2 Reticulocytopenic anemia is a rare ADE from prolonged quinupristin-dalfopristin use. This report describes the third case of severe but reversible reticulocytopenic anemia due to quinupristin-dalfopristin.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.